{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T08:28:31Z","timestamp":1772699311218,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T00:00:00Z","timestamp":1523404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Becton, Dickinson and Company"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ygyno.2018.04.007","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T02:21:26Z","timestamp":1524104486000},"page":"498-505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results"],"prefix":"10.1016","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2784-1008","authenticated-orcid":false,"given":"Mark H.","family":"Stoler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Thomas C.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Parvu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Vaughan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Yanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobi","family":"Karchmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma","family":"Kodsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles K.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2018.04.007_bb0005","first-page":"147","article-title":"American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer","volume":"62","author":"Saslow","year":"2012","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2018.04.007_bb0010","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ygyno.2014.12.022","article-title":"Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance","volume":"136","author":"Huh","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.04.007_bb0015","series-title":"Cobas\u00ae 4800 HPV Test [Package Insert, CE]","year":"2015"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0020","author":"U.S. Preventive Services Task Force"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0025","author":"Royal Australian College of General Practitioners"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0030","author":"Ponti"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0035","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cmi.2015.04.015","article-title":"Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?","volume":"21","author":"Arbyn","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ygyno.2018.04.007_bb0040","first-page":"255","article-title":"Human papillomaviruses","volume":"100B","author":"International Agency for Research on Cancer","year":"2012","journal-title":"IARC Monogr. Eval. Carcinog. Risks Hum."},{"key":"10.1016\/j.ygyno.2018.04.007_bb0045","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1309\/RNF3C01JKADQCLKP","article-title":"The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays","volume":"127","author":"Stoler","year":"2007","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ygyno.2018.04.007_bb0050","series-title":"Hybrid Capture\u00ae 2 High-risk HPV DNA Test [Package Insert]","year":"2004"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0055","series-title":"Cervista\u2122 HPV HR [Package Insert]","year":"2016"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0060","series-title":"Aptima\u00ae HPV Assay [Package Insert]","year":"2007"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0065","series-title":"Cervista\u2122 HPV 16\/18 [Package Insert]","year":"2011"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0070","series-title":"APTIMA\u00ae HPV 16 18\/45 Genotype Assay [Package Insert]","year":"2007"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0075","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pvr.2016.01.003","article-title":"Clinical and analytical performance of the BD Onclarity HPV assay for detection of CIN2+ lesions on SurePath samples","volume":"2","author":"Ejegod","year":"2016","journal-title":"Papillomavirus Res."},{"key":"10.1016\/j.ygyno.2018.04.007_bb0080","series-title":"Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Human Papillomaviruses: Guidance for Industry and Food and Drug Administration Staff","author":"Food and Drug Administration","year":"2011"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0085","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.287.16.2114","article-title":"The 2001 Bethesda System: terminology for reporting results of cervical cytology","volume":"287","author":"Solomon","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0090","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1309\/AJCP53KMHNRDICBL","article-title":"Clinical performance of the BD Onclarity HPV assay using an adjudicated cohort of BD SurePath liquid-based cytology specimens","volume":"142","author":"Wright","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ygyno.2018.04.007_bb0095","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.5858\/arpa.LGT200570","article-title":"The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology","volume":"136","author":"Darragh","year":"2012","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.ygyno.2018.04.007_bb0100","series-title":"Statistical Analysis With Missing Data","author":"Little","year":"2002"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0105","series-title":"GARDASIL\u00ae9 (Human Papillomavirus 9-Valent Vaccine, Recombinant) Suspension for Intramuscular Injection [Package Insert]","year":"2014"},{"issue":"46","key":"10.1016\/j.ygyno.2018.04.007_bb0110","first-page":"e1","article-title":"The ATHENA human papillomavirus study: design, methods, and baseline results","volume":"206","author":"Wright","year":"2012","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2018.04.007_bb0115","author":"U.S. Census Bureau"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0120","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/ijc.28514","article-title":"Interlaboratory variation in the performance of liquid-based cytology: insights from the ATHENA trial","volume":"134","author":"Wright","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ygyno.2015.01.551","article-title":"Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial","volume":"137","author":"Monsonego","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.04.007_bb0130","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/jnci\/95.1.46","article-title":"Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis","volume":"95","author":"Sherman","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2018.04.007_bb0135","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.297.8.813","article-title":"Prevalence of HPV infection among females in the United States","volume":"297","author":"Dunne","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0140","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1186\/1471-2334-14-413","article-title":"HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 human papillomavirus genotype microarray system","volume":"14","author":"Bonde","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.ygyno.2018.04.007_bb0145","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1186\/s12889-016-3581-0","article-title":"Pre-vaccine era cervical human papillomavirus infection among screening population of women in West Austria","volume":"16","author":"Borena","year":"2016","journal-title":"BMC Public Health"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0150","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1002\/ijc.27891","article-title":"Prevalence and viral load of 51 genital human papillomavirus types and three subtypes","volume":"132","author":"Schmitt","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0155","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1186\/s12885-016-2961-2","article-title":"HPV prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows","volume":"16","author":"Huijsmans","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0160","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1089\/jwh.2011.3385","article-title":"Cervical cancer trends in the United States: a 35-year population-based analysis","volume":"21","author":"Adegoke","year":"2012","journal-title":"J. Women's Health (Larchmt)"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0165","author":"Bruni"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0170","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/cncr.28548","article-title":"Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009","volume":"120","author":"Rositch","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0175","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1001\/jama.294.17.2173","article-title":"Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial","volume":"294","author":"Denny","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0180","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.288.14.1749","article-title":"Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral","volume":"288","author":"Kulasingam","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0185","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/sim.907","article-title":"Estimating prevalence when the true disease status is incompletely ascertained","volume":"20","author":"Sasieni","year":"2001","journal-title":"Stat. Med."},{"key":"10.1016\/j.ygyno.2018.04.007_bb0190","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.04.007_bb0195","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/ijc.27485","article-title":"Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer","volume":"131","author":"Guan","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.04.007_bb0200","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1002\/ijc.30375","article-title":"A cohort study of cervical screening using partial HPV typing and cytology triage","volume":"139","author":"Schiffman","year":"2016","journal-title":"Int. J. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818302841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818302841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:42:10Z","timestamp":1758771730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818302841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0090825818302841"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.04.007","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}